SOURCE: Market Pulse

April 13, 2010 08:30 ET

Market Pulse Breaking News Alert for Tuesday, April 13, 2010: MZEI -- Medizone International to Greatly Increase Exposure for Its Phenomenal Product AsepticSure™!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA--(Marketwire - April 13, 2010) -  Market Pulse News Alert for this AM, Stocks to Watch are: Medizone International, Inc. (OTCBB: MZEI), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Ambac Financial Group Inc. (NYSE: ABK) and Palm Inc. (NASDAQ: PALM).

Investors need to be watching Medizone International, Inc. (OTCBB: MZEI) this AM! Medizone International is a research and development company engaged in developing AsepticSure™ System, a novel ozone-based technology. AsepticSure™ is a portable decontamination and sterilization system for hospitals, government buildings, sports training facilities, schools and other critical infrastructure that might currently require, or need to be prepared for countermeasures capability from contamination by infectious biological agents. A government variant is being developed for bio-terrorism counter measures. Medizone began mockup trials in January 2010 for both public (hospital) and government (bio-terrorism countermeasures) applications. In March 2010, Medizone successful completed the first full round of room scale testing with its AsepticSure™ sterilization system. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis. The AsepticSure™ system is capable of decontamination to the previously unobtainable 6 log standard (99.9999% bactericidal kill) on all hospital surfaces, hard or soft. Medizone is now able to greatly reduce the time required to achieve 6 log kills on hard surfaces to 30 minutes of exposure. From a commercial viewpoint, the higher the "kill rate" in the shortest turn around time, the more favorably physicians and hospital administrators will view the system. Given the outstanding range of bactericidal kill rates Medizone has achieved to date with the pathogens most often associated with hospital derived infections, it has become clear there are opportunities abounding to expand scientific horizons through collaborative arrangements in many diverse and exciting new applications. Biological contamination of medical treatment areas such as hospitals and chronic care facilities has recently been identified by several world renowned public health institutions, including the Centers for Disease Control, as one of the greatest threats to public health and safety in the industrial world. Hospital Acquired Infections (HAIs) are one of the most common complications of hospital care. Nearly 2 million patients develop HAIs, which contribute to 99,000 deaths each year and $28 billion to $33 billion in health care costs. Demand for an effective product is huge. Once the trial program for the AsepticSure™ hospital sterilization system is concluded, MZEI expects to out-source the manufacturing of the product and partner with large, well established companies that are already fully embedded in their sector of business as suppliers, such as medical device manufacturers or service companies. Medizone believes that a field hardened variant of the AsepticSure™ hospital unit currently being readied for scale up testing will have wide bio defense applications internationally as it will be easily deployable in response to virtually any terrorist assault, extremely effective against a broad range of lethal pathogens, easy to manage and maintain and most importantly, it has the potential to save lives. Medizone now believes that the performance profile of its AsepticSure™ Sterilization System will exceed all the prerequisite requirements of affordability, practicability and unmatched efficacy, which will catapult it into the world market. Medizone International, Inc. is poised to become a significant player in the healthcare industry! Medizone International, Inc. just had excellent news out in a press release before today's opening bell announcing they are planning to greatly increase the exposure for its phenomenal product AsepticSure™! This could be great news for investors!

Medizone International, Inc. (OTCBB: MZEI) announces it will be attending the Accredited Members, Inc. conference being held at the Green Valley Ranch Resort in Las Vegas, Nevada between April 20th and 22nd. Accredited Members sponsors a number of conferences each year, which interface emerging companies such as Medizone International with previously qualified high net worth accredited investors looking for new opportunities.

Edwin Marshall, Medizone's CEO and Board Chairman who will be attending, commented, "I am pleased to have been invited to this conference and enthused about the opportunity to showcase Medizone and our AsepticSure™ technology to an estimated three hundred qualified investors at one time. As we are about to start our hospital beta test program, we must also look forward to our projected capital requirements for entering production and sales later this year. I believe by attending this conference and the Vail conference scheduled for June 7-9, it is likely we will be able to fully fund all of our needs through initial production." Mr. Marshall went on to say, "Another bonus to the conference is the opportunity to be introduced to the global audience of Don Baillargeon's MoneyTV show, as he will be filming a segment of the show at the conference. MoneyTV has been on the air for more than 14 years and over 650 episodes. They have a global distribution of 170 million TV households. The US distribution is more than 70 million TV households. My personal opinion is that our stock price is currently significantly undervalued. I expect our presence at the upcoming conferences in Las Vegas and Vail, combined with being on MoneyTV, will greatly increase the number of eyes on Medizone and our phenomenal product, AsepticSure™."

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Research is conducted at Medizone's dedicated laboratories located in Innovation Park, Queen's University in Kingston, Ontario, Canada.

Stocks in the news and acting well as of late include: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Ambac Financial Group Inc. (NYSE: ABK) and Palm Inc. (NASDAQ: PALM).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated five thousand dollars from Medizone International, Inc. In addition, MP was also compensated two hundred fifty thousand restricted shares of Medizone International, Inc. by the company. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information